Hat mitgewirkt an:
-
Nascent proteome analysis of MAPK and PI3K-AKT-mTOR oncogenic signaling pathways
-
Raman micro-spectroscopy monitors acquired resistance to targeted cancer therapy at the cellular level
-
Raman Microspectroscopic Evidence for the Metabolism of a Tyrosine Kinase Inhibitor, Neratinib, in Cancer Cells
-
A single-sample workflow for joint metabolomic and proteomic analysis of clinical specimens